← All organizations
Highest phase reached
Phase 2
First clinical trial
Jan 1, 2014Last known activity
Sep 1, 2025
Timeline
2010s
- Jan 1, 2014
Shenzhen Geno-Immune Medical Institute— Founded
Drugs by trial phase (57 distinct, 60 trials)
Phase 2 (45 own, 0 via acquisition)
Phase 1 (8 own, 0 via acquisition)
Indications
Studied for
- Acute Disease
- Adenoviridae Infections
- Breast Neoplasms
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Communicable Diseases
- Cytomegalovirus Infections
- Disease
- Epstein-Barr Virus Infections
- Glioblastoma
- Glioma
- Hemophilia A
- Hemophilia B
- Infections
- Leukemia
- Leukemia, B-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Multiple Myeloma
- Mycoses
- Myelodysplastic Syndromes
- Neoplasms
- Neoplasms, Plasma Cell
- Neuroblastoma
- Opportunistic Infections
- Ovarian Neoplasms
- Papilloma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Sarcoma
- Sarcoma, Ewing
- Tuberculosis
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
- X-Linked Combined Immunodeficiency Diseases
Recent trials (50)
- NCT07193966Lead sponsorPhase 1/Phase 2Sep 1, 2025
- NCT06739226Lead sponsorPhase 1/Phase 2Dec 10, 2024
- NCT06435897Lead sponsorPhase 1/Phase 2May 15, 2024
- NCT05995041Lead sponsorPhase 1Oct 31, 2023
- NCT05995015Lead sponsorPhase 1Oct 31, 2023
- NCT05995028Lead sponsorPhase 1Oct 31, 2023
- NCT05459870Lead sponsorPhase 1/Phase 2Jul 31, 2022
- NCT05436509Lead sponsorPhase 1/Phase 2Jun 30, 2022
- NCT05437328Lead sponsorPhase 1/Phase 2Jun 30, 2022
- NCT05437341Lead sponsorPhase 1/Phase 2Jun 30, 2022
- NCT05432882Lead sponsorPhase 1/Phase 2Jun 30, 2022
- NCT05437315Lead sponsorPhase 1/Phase 2Jun 30, 2022
- NCT05436496Lead sponsorPhase 1/Phase 2Jun 30, 2022
- NCT05438368Lead sponsorPhase 1/Phase 2Jun 30, 2022
- NCT04637503Lead sponsorPhase 1/Phase 2Nov 18, 2020
Details
- Founded
- Shenzhen, CN Jan 1, 2014
- Last known activity
- Sep 1, 2025